Table 4.

Reimbursement Costs, by HEC or MEC at Time of Clinic Visit for Unscheduled Hydration

Cost component	Per-patient reimbursement costsa						Per-patient reimbursement costs (patients requiring additional costs)a
	SC granisetron ER cohort, $ (N = 55)	Palonosetron cohort, $ (N = 76)	P valueb	SC granisetron ER cohort, $ (N = 36)	Palonosetron cohort, $ (N = 15)	P valueb	SC granisetron ER cohort, $ (N = 23)	Palonosetron cohort, $ (N = 62)	P valueb	SC granisetron ER cohort, $ (N = 16)	Palonosetron cohort, $ (N = 10)	P valueb
Unscheduled hydration	66	280	<.0001	57	115	.1079	158c	344	.0425	128	173	.4908
Rescue antiemetic administration	63	155	<.0001	28	66	.0986	151	190	.1674	63	99	.6083
Rescue antiemetic drugs	79	137	<.0001	32	3	.1939	190	168	.3373	73	4	1.0000
Laboratory	18	55	<.0001	13	21	.1900	44	68	.1691	29	32	.8946
Office evaluation	117	306	.0007	93	143	.5675	280	374	.6478	208	215	.4742
Total	343	933	<.0001	223	348	.2219	823	1144	.1240	501	523	.8536

^aValues represent the mean.

^bP values are from Wilcoxon rank-sum test.

^cN = 22; 1 patient did not receive hydration but received other components of care.

ER indicates extended-release; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; SC, subcutaneous.